Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Treatment of Relapsed Agressive Lymphomas

NCT00842595 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT00842595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00842595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Treatment of Relapsed Agressive Lymphomas
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
May 31, 2010
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma